Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
up to 70 Years (Child, Adult, Senior)
Sexes Eligible for Study:
Undifferentiated or non-keratinizing carcinoma
Tumor staged as T3-4 AND N0-1
No evidence of distant metastasis (M0)
Performance status: 0-2
Marrow: WBC >= 4 and platelet = 100
Renal: creatinine clearance = 60
WHO type I squamous cell carcinoma or adenocarcinoma
Age >= 70
Palliative intent or tumor extent mandating AP opposing facio-cervical fields
Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years
Keywords provided by Hospital Authority, Hong Kong:
Additional relevant MeSH terms:
Nasopharyngeal Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms
Head and Neck Neoplasms Neoplasms by Site Nasopharyngeal Diseases Neoplasms, Squamous Cell
Carcinoma, Squamous Cell